ICON Public (NASDAQ:ICLR) Lowered to “Neutral” Rating by The Goldman Sachs Group

The Goldman Sachs Group lowered shares of ICON Public (NASDAQ:ICLR) from a buy rating to a neutral rating in a research note issued to investors on Friday, MarketBeat Ratings reports. They currently have $200.00 price target on the medical research company’s stock, down from their prior price target of $250.00.

ICLR has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $263.00 target price on shares of ICON Public in a research note on Wednesday, January 15th. Barclays decreased their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research note on Friday, February 21st. Robert W. Baird cut their price objective on ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Truist Financial decreased their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $272.50.

ICON Public Price Performance

Shares of ICON Public stock opened at $184.87 on Friday. The firm has a market cap of $14.93 billion, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.86 and a beta of 1.21. The company’s fifty day simple moving average is $192.76 and its two-hundred day simple moving average is $226.90. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. ICON Public has a 12-month low of $174.93 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. As a group, equities analysts expect that ICON Public will post 13.38 EPS for the current year.

Hedge Funds Weigh In On ICON Public

Hedge funds have recently bought and sold shares of the company. Foyston Gordon & Payne Inc raised its holdings in ICON Public by 27.3% in the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock worth $10,845,000 after buying an additional 11,089 shares during the last quarter. Captrust Financial Advisors raised its holdings in ICON Public by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock worth $7,403,000 after acquiring an additional 701 shares during the last quarter. State of Tennessee Department of Treasury raised its holdings in ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock worth $33,333,000 after acquiring an additional 1,600 shares during the last quarter. Motley Fool Wealth Management LLC lifted its position in ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after acquiring an additional 1,466 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in ICON Public by 128.2% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 655 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.